Trials / Terminated
TerminatedNCT04686786
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
A 57-Week, Multicenter, Active-treatment, Open-label Extension Trial of CVL-865 as Adjunctive Therapy in Adults With Drug-Resistant Focal Onset Seizures
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the long-term safety and tolerability of CVL-865 as adjunctive therapy in participants with focal onset seizures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CVL-865 | Participants will receive 25 mg CVL-865 tablets orally BID during the treatment period. The dose may be decreased to 17.5 mg BID for tolerability. |
Timeline
- Start date
- 2020-12-08
- Primary completion
- 2024-12-05
- Completion
- 2024-12-05
- First posted
- 2020-12-29
- Last updated
- 2025-12-11
- Results posted
- 2025-12-11
Locations
56 sites across 7 countries: United States, Australia, Poland, Serbia, South Korea, Spain, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04686786. Inclusion in this directory is not an endorsement.